San Francisco, CA -- (SBWIRE) -- 09/25/2014 -- CMEA Capital portfolio company Neos Therapeutics, Inc. ("Neos" or "the Company"), a specialty pharmaceutical company with highly differentiated proprietary oral drug delivery technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, announced that it has acquired all commercialization rights to its Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended Release Suspension Product from partners Chiesi USA, Inc., and Coating Place, Inc. This product is a generic equivalent to the Tussionex® brand drug and provides relief of upper respiratory and cough symptoms from allergy / cold in adults and children above six years of age.

Neos also announced that it has settled all pending litigation related to its amphetamine polistirex orally disintegrating tablet (known as NT-0202, which treats ADHD). This drug is positioned to be the first-ever, extended release orally disintegrating tablet for treating ADHD. Shire LLC had filed suit on April 11, 2013 against Neos, alleging that the latter infringed on US Patent Nos. RE 42096 and 41148. The two parties have now entered into an agreement that provides the Company with a license to make, market, and sell NT-0202 with royalties through the expiration of the patents.
About Neos Therapeutics

Neos Therapeutics, Inc. is a fully integrated specialty pharmaceutical company. The Company is initially focusing on ADHD with three proprietary products in late-stage development that provide patient-friendly dosage forms incorporating controlled and extended release oral disintegrating tablets (ODT) and liquid suspensions. In addition, Neos manufactures and markets a generic of Tussionex® for the treatment of cough and cold. The Company's products are developed and manufactured using its proprietary and patented ion resin technology. For more information, visit www.neostx.com.

This press release contains certain forward-looking statements that include projections and may also include words such as may, will, expects, believes, anticipates, plans, estimates, seeks, could, intends, and other similar expressions. These forward-looking statements involve risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to vary materially from what is expressed in or indicated by the forward-looking statements.

About CMEA Capital
CMEA Capital is a San Francisco-based venture capital firm with a clear focus on life sciences, high technology, and energy and materials investments. They believe that the most successful venture backed companies are those that are science based, with experienced teams that have a vision. As a result, CMEA Capital typically invests in companies that have cutting edge and highly differentiated technology at their core and founding teams of the highest caliber still in place. These are companies that have the potential to transform their industries.

Press Relations Contact:
Victoria Jenks
victoria@cmea.com
ph: 415-352-1520

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

CMEA Capital portfolio company Arcadia Biosciences, Inc. announces closing of $33 million round of series D preferred share equity financing. Arcadia Biosciences, Inc. is an agricultural biotechnology company that concentrates only on developing technologies and products, which in coming times will benefit the environment and human health.

San Francisco, CA -- (SBWIRE) -- 06/25/2014 -- CMEA Capital portfolio company Arcadia Biosciences, Inc. announces closing of $33 million round of series D preferred share equity financing. Arcadia Biosciences, Inc. is an agricultural biotechnology company that concentrates only on developing technologies and products, which in coming times will benefit the environment and human health. With an aim to speed up the development and commercial launch of products primarily based on the company's agronomic performance and product quality, they planned to utilize profits from the financing.

CMEA Capital along with the other investors participated in the round that headed with an investment of $30 million from Mandala Capital Limited. In addition, the Series D round completed with a total equity capital raised by Arcadia amounts to $101 million.

Besides, Eric Rey, President and CEO of Arcadia mentions for CMEA Capital, "Multiple products based on Arcadia's agronomic performance and product quality traits are currently in late-stage commercial development, and our SONOVA® 400 GLA Safflower Oil is already on market. The Series D funding enables us to continue working closely with our licensees and partners to accelerate progress, provide key data for commercial regulatory approvals, and pursue opportunities with new partners."

The company has a strong network of corporate, investment, and entrepreneurial relationships, thus, invests in both early and late stage ventures. From the inception, they have successfully managed seven venture capital funds representing investments in excess of $1.2 billion.

About CMEA Capital
CMEA Capital is a San Francisco-based venture capital firm with a clear focus on life sciences, high technology, and energy and materials investments. They believe that the most successful venture backed companies are those that are science based, with experienced teams that have a vision. As a result, CMEA Capital typically invests in companies that have cutting edge and highly differentiated technology at their core and founding teams of the highest caliber still in place. These are companies that have the potential to transform their industries.

For more information, please visit- http://www.cmea.com/about-us/

Contact Details

1 Letterman Drive
Building C, Suite CM500
San Francisco, CA 94129
Phone: (415) 352-1520
Fax: (415) 352-1524

Press Relations Contact
For press inquiries only, please contact:
Contact: Victoria Jenks
Email: victoria@cmea.com
Phone: (415) 352-1520

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm